Physician profile
Anna E Johnson
NPI 1912342510
$2,937.96
in general payments reported to CMS, 2019-2025
28 companies · $1,838 in 2025
The $1,838 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $70.68 · 2024: $882 · 2025: $1,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,541 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.55 |
| Education | $179.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $375.13 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Daiichi Sankyo INC. | $338.37 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $307.76 | 2024-2025 | |
| Pfizer INC. | $282.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $258.92 | 2020-2025 | Tagrisso, Imfinzi, Calquence |
| Janssen Biotech, INC. | $226.67 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Abbvie INC. | $215.70 | 2024-2025 | |
| Astellas Pharma US INC | $150.02 | 2024-2025 | Vyloy, Xtandi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.25 | 2019-2025 | Jardiance |
| Incyte Corporation | $95.93 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Gilead Sciences, INC. | $84.99 | 2024 | Trodelvy |
| Glaxosmithkline, LLC. | $72.52 | 2024-2025 | Zejula, Ojjaara |
| Allergan, INC. | $57.84 | 2019-2020 | |
| Exelixis INC. | $47.56 | 2024-2025 | Cabometyx |
| Celgene Corporation | $41.28 | 2025 | Breyanzi, Reblozyl |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $39.91 | 2025 | Tivdak |
| Genentech USA, INC. | $39.39 | 2019-2024 | Tecentriq, Phesgo, Columvi |
| Amgen INC. | $35.00 | 2019 | |
| Stemline Therapeutics INC. | $21.06 | 2025 | Orserdu |
| Sun Pharmaceutical Industries INC. | $18.34 | 2024 | |
| Legend Biotech USA INC. | $18.21 | 2025 | Carvykti |
| Celltrion USA INC. | $17.72 | 2025 | Vegzelma |
| Sumitomo Pharma America, INC. | $17.18 | 2024 | Orgovyx |
| Lilly USA, LLC | $16.95 | 2024 | Verzenio, Retevmo, Jaypirca |
| Genzyme Corporation | $15.64 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $15.42 | 2025 | Opdivo |
| Ipsen Biopharmaceuticals, INC | $15.25 | 2025 | Onivyde |
| Sunovion Pharmaceuticals INC. | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.